| Long-Term Effects of COVID-19 | Lifetime | 609 | IQ 2 | 95.80 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 466 | IQ 2 | 92.18 |
| COVID-19 Impact on Reproduction | Lifetime | 656 | IQ 2 | 89.23 |
| GDF15 and Related Biomarkers | Lifetime | 380 | IQ 2 | 85.03 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 673 | IQ 4 | 71.15 |
| Andrographolide Research and Applications | Lifetime | 674 | IQ 4 | 48.11 |
| COVID-19 Clinical Research Studies | 2021-2025 | 853 | IQ 2 | 96.48 |
| COVID-19 Impact on Reproduction | 2021-2025 | 283 | IQ 2 | 91.70 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 142 | IQ 3 | 91.49 |
| Nuclear Receptors and Signaling | 2021-2025 | 62 | IQ 3 | 88.03 |
| Inflammasome and immune disorders | 2021-2025 | 487 | IQ 2 | 87.93 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 367 | IQ 2 | 86.36 |
| Peptidase Inhibition and Analysis | 2021-2025 | 769 | IQ 1 | 87.95 |
| Autophagy in Disease and Therapy | 2021-2025 | 760 | IQ 4 | 84.13 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 261 | IQ 2 | 82.85 |
| Pharmacological Receptor Mechanisms and Effects | 2021-2025 | 106 | IQ 2 | 82.52 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 723 | IQ 2 | 82.77 |
| Nerve injury and regeneration | 2021-2025 | 339 | IQ 2 | 82.77 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 355 | IQ 2 | 81.89 |
| Vitamin C and Antioxidants Research | 2021-2025 | 199 | IQ 2 | 80.90 |
| Kruppel-like factors research | 2021-2025 | 162 | IQ 2 | 79.92 |
| GDF15 and Related Biomarkers | 2021-2025 | 151 | IQ 2 | 77.14 |
| Erythrocyte Function and Pathophysiology | 2021-2025 | 447 | IQ 2 | 79.75 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 661 | IQ 4 | 77.90 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 717 | IQ 2 | 76.48 |
| Renin-Angiotensin System Studies | 2021-2025 | 132 | IQ 2 | 76.13 |
| Adenosine and Purinergic Signaling | 2021-2025 | 416 | IQ 2 | 75.37 |
| Heme Oxygenase-1 and Carbon Monoxide | 2021-2025 | 486 | IQ 2 | 70.80 |
| Andrographolide Research and Applications | 2021-2025 | 59 | IQ 2 | 64.92 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 434 | IQ 2 | 70.17 |
| S100 Proteins and Annexins | 2021-2025 | 588 | IQ 2 | 68.18 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 553 | IQ 1 | 67.66 |
| Vagus Nerve Stimulation Research | 2021-2025 | 504 | IQ 2 | 66.18 |
| Fibroblast Growth Factor Research | 2021-2025 | 600 | IQ 2 | 65.35 |
| Calcium signaling and nucleotide metabolism | 2021-2025 | 325 | IQ 2 | 61.22 |
| Cerebrovascular and genetic disorders | 2021-2025 | 297 | IQ 1 | 62.20 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 693 | IQ 2 | 60.49 |
| Chemotherapy-induced organ toxicity mitigation | 2021-2025 | 394 | IQ 3 | 55.97 |
| Sirtuins and Resveratrol in Medicine | 2021-2025 | 895 | IQ 4 | 55.23 |
| Blood properties and coagulation | 2021-2025 | 921 | IQ 2 | 54.19 |
| Biochemical Acid Research Studies | 2021-2025 | 287 | IQ 2 | 51.04 |
| Berberine and alkaloids research | 2021-2025 | 544 | IQ 2 | 48.75 |
| Macrophage Migration Inhibitory Factor | 2021-2025 | 434 | IQ 2 | 45.66 |